BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search
 Company Profile

 

Systems Medicine LLC 

4320 North Campbell Avenue
Suite 226
Tucson  Arizona  85718  U.S.A.
Phone: 520-750-1488 Fax: 520-382-1036


SEARCH JOBS




Industry
Biotechnology






 Company News
Systems Medicine LLC Release: Genes Identified That Enhance Tumor Cell Sensitivity to CTI's Cancer Drug Brostallicin 4/21/2009 9:53:22 AM
Systems Medicine LLC Uses OmniComm Systems, Inc. (OMCM) for Electronic Data Capture (EDC) in a Phase II Oncology Study 8/21/2008 9:10:10 AM
Systems Medicine LLC New Gene Discovery Suggests Which Patients CTI's Brostallicin May Benefit Cancer 4/14/2008 10:05:02 AM
Pharmatech, Inc. Teams up With Systems Medicine LLC and the Sarcoma Foundation of America for a Phase II Myxoid Liposarcoma Trial 3/3/2008 9:46:45 AM
Systems Medicine Study Shows Brostallicin in Combination with Cisplatin is Well-Tolerated and Produces Prolonged Disease Stabilization in Patients with Platinum-Resistant Cancers 9/27/2007 11:06:52 AM
Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTIC), Announces Execution of CRADA with National Cancer Institute / National Institutes of Health (NIH) to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway 8/22/2007 9:07:24 AM